Fusion Antibodies has delivered a materially improved FY2026 performance, with revenue growth of 9%, a remarkable gross margin expansion from 22% to 50%, and a cash position that has more than doubled to £1.04m. While the absolute revenue figure of £2.13m remains modest and the company is still in recovery mode, the directional indicators are encouraging: margin quality is improving, the customer base is getting more diverse, a more differentiate pipeline development, more creditworthy pharmaceu ....